LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (23rd October 2018) - Cappuzzo, F; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, H J; Kopp, H-G; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; et al.